526e2e75-cc0e-4c03-916c-908fbc271854
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.480
- IL6_JAK_STAT3_SIGNALING+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- FATTY_ACID_METABOLISM+0.370
- INFLAMMATORY_RESPONSE+0.370
- COMPLEMENT+0.310
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.340
- UV_RESPONSE_DN-0.270
- WNT_BETA_CATENIN_SIGNALING-0.260
- MYC_TARGETS_V2-0.250
- SPERMATOGENESIS-0.220
- PROTEIN_SECRETION-0.180
- TGF_BETA_SIGNALING-0.160
- G2M_CHECKPOINT-0.140
- MITOTIC_SPINDLE-0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR9879272 | — | cohortSQ1 | 0.852 |
| 2 | BS_R634WKN7 | subependymal giant cell astrocytoma(SEGA) | — | 0.841 |
| 3 | 34b0602a-c93d-4734-b860-a2cb66091e2e | — | — | 0.836 |
| 4 | SRR1369148 | GTEX | — | 0.835 |
| 5 | DRR168511 | — | — | 0.833 |
| 6 | BS_CS66RYDA | Schwannoma | — | 0.832 |
| 7 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.831 |
| 8 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.831 |
| 9 | BS_3TQSE8HF | subependymal giant cell astrocytoma(SEGA) | — | 0.826 |
| 10 | BS_JG9JZTA9 | low-grade glioma | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |